Mostrar el registro sencillo del ítem
dc.contributor.author | Alexandrou, María Eleni | |
dc.contributor.author | Papagianni, Aikaterini | |
dc.contributor.author | Tsapas, Apostolos | |
dc.contributor.author | Loutradis, Charalampos | |
dc.contributor.author | Boutou, Afroditi | |
dc.contributor.author | Piperidou, Alexia | |
dc.contributor.author | Papadopoulou, Dorothea | |
dc.contributor.author | Ruilope Urioste, Luis Miguel | |
dc.contributor.author | Bakris, George | |
dc.contributor.author | Sarafidis, Pantelis A. | |
dc.date.accessioned | 2020-01-30T18:52:34Z | |
dc.date.available | 2020-01-30T18:52:34Z | |
dc.date.issued | 2019 | |
dc.identifier.citation | Alexandrou, M. E., Papagianni, A., Tsapas, A., Loutradis, C., Boutou, A., Ruilope, L. M., … Sarafidis, P. (2019). Effects of mineralocorticoid receptor antagonists in proteinuric kidney disease: A systematic review and meta-analysis of randomized controlled trials . Journal of Hypertension, 37(12), 2307–2324. https://doi.org/10.1097/HJH.0000000000002187 | spa |
dc.identifier.issn | 0263-6352 | |
dc.identifier.issn | 1473-5598 | |
dc.identifier.uri | http://hdl.handle.net/11268/8559 | |
dc.description.abstract | Background: Reductions in albuminuria of more than 30% are considered a strong marker of delay of chronic kidney disease (CKD) progression. Single renin–angiotensin system (RAS) blockade represents the cornerstone of CKD treatment. However, as CKD progression still occurs, other nephroprotective options were explored; mineralocorticoid receptor antagonists (MRA) were tested with generally positive results. Methods: We conducted a systematic review and meta-analysis on the effects of MRAs on albuminuria/proteinuria, and adverse events, such as change in renal function and hyperkalemia incidence. A detailed search in electronic databases, clinical trial registries and grey literature was performed to retrieve randomized controlled trials (RCTs) in which administration of an MRA alone or on-top of ACEi/ARB was compared with placebo or active treatment. Results: Of the 45 initially identified reports, 31, with 2767 participants, were included in analysis of the primary outcome. The use of MRAs (alone or on top of RAS blockade) compared with placebo decreased urine albumin-to-creatinine ratio (UACR) by −24.55% (95% CI −29.57 to −19.53%), urine protein-to-creatinine ratio (UPCR) by −53.93% (95% CI −79% to −28.86%) and 24 h albumin excretion by −32.47% (95% CI −41.1 to −23.85%). MRAs also reduced UACR by −22.48% (95% CI −24.51 to −20.44%) compared with calcium-channel-blockers (CCBs), whereas no differences were found compared with a second ACEi/ARB or nonpotassium-sparing diuretics. Addition of an MRA was associated with change in estimated glomerular filtration rate (eGFR) of −2.38 ml/min per 1.73 m2 (95% CI −3.51 to −1.25), rise in potassium by 0.22 mEq/l (95% CI 0.16–0.28 mEq/l) and a 2.6-fold increase in hyperkalemia risk (RR 2.63, 95% CI 1.69–4.08) compared with placebo/active control. Conclusion: Use of MRAs alone or on top of RAS blockade confers important antiproteinuric effects in patients with CKD, with a slight increase in mean potassium levels. | spa |
dc.description.sponsorship | Sin financiación | spa |
dc.language.iso | eng | spa |
dc.title | Effects of mineralocorticoid receptor antagonists in proteinuric kidney disease: A systematic review and meta-analysis of randomized controlled trials | spa |
dc.type | article | spa |
dc.description.impact | 4.171 JCR (2019) Q1, 13/65 Peripheral Vascular Disease | spa |
dc.description.impact | 1.365 SJR (2019) Q1, 42/186 Physiology, 65/362 Cardiology and Cardiovascular Medicine, 21/139 Internal Medicine | spa |
dc.description.impact | No data IDR 2019 | spa |
dc.identifier.doi | 10.1097/HJH.0000000000002187 | |
dc.rights.accessRights | closedAccess | spa |
dc.subject.uem | Aparato circulatorio | spa |
dc.subject.uem | Enfermedades | spa |
dc.subject.unesco | Sistema cardiovascular | spa |
dc.subject.unesco | Enfermedad cardiovascular | spa |
dc.description.filiation | UEM | spa |
dc.peerreviewed | Si | spa |
Ficheros | Tamaño | Formato | Ver |
---|---|---|---|
No hay ficheros asociados a este ítem. |